REATA PHARMACEUTICALS INC-A (RETA) Stock Price, Quote, News and Overview
NASDAQ:RETA - Nasdaq - US75615P1030 - Common Stock - Currency: USD
RETA Quote, Performance and Key Statistics
172.36
+0.04 (+0.02%)
The current stock price of RETA is 172.36 USD. In the past month the price increased by 1.99%. In the past year, price increased by 585.87%.
RETA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.98 | 678.00B | ||
| JNJ | JOHNSON & JOHNSON | 15.19 | 367.19B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.48 | 302.61B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.54 | 222.20B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.8 | 216.87B | ||
| MRK | MERCK & CO. INC. | 9.99 | 195.88B | ||
| PFE | PFIZER INC | 7.18 | 130.67B | ||
| SNY | SANOFI-ADR | 13.71 | 128.55B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.41 | 95.71B | ||
| GSK | GSK PLC-SPON ADR | 7.06 | 78.75B | ||
| ZTS | ZOETIS INC | 26.91 | 72.25B | ||
| HLN | HALEON PLC-ADR | 22.57 | 49.87B |
Related stock screener links
About RETA
Company Profile
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. The company is headquartered in Plano, Texas and currently employs 321 full-time employees. The company went IPO on 2016-05-26. The firm concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. The firm's first product, SKYCLARYS (omaveloxolone), is used for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. The company is also engaged in developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications and Nrf2 activators for neurological diseases. Omaveloxolone activates the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation, in nonclinical models. Its Nrf2 activators are applicable to both rare diseases, such as Huntington's disease, progressive supranuclear palsy, frontotemporal dementia, primary progressive multiple sclerosis, and others.
Company Info
REATA PHARMACEUTICALS INC-A
5320 Legacy Dr
Plano TEXAS 75024 US
CEO: J. Warren Huff
Employees: 321
Phone: 19728652219.0
REATA PHARMACEUTICALS INC-A / RETA FAQ
What is the stock price of REATA PHARMACEUTICALS INC-A today?
The current stock price of RETA is 172.36 USD. The price increased by 0.02% in the last trading session.
What is the ticker symbol for REATA PHARMACEUTICALS INC-A stock?
The exchange symbol of REATA PHARMACEUTICALS INC-A is RETA and it is listed on the Nasdaq exchange.
On which exchange is RETA stock listed?
RETA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REATA PHARMACEUTICALS INC-A stock?
15 analysts have analysed RETA and the average price target is 175.9 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 172.36. Check the REATA PHARMACEUTICALS INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REATA PHARMACEUTICALS INC-A worth?
REATA PHARMACEUTICALS INC-A (RETA) has a market capitalization of 5.79B USD. This makes RETA a Mid Cap stock.
How many employees does REATA PHARMACEUTICALS INC-A have?
REATA PHARMACEUTICALS INC-A (RETA) currently has 321 employees.
What are the support and resistance levels for REATA PHARMACEUTICALS INC-A (RETA) stock?
REATA PHARMACEUTICALS INC-A (RETA) has a support level at 172.13 and a resistance level at 172.37. Check the full technical report for a detailed analysis of RETA support and resistance levels.
Is REATA PHARMACEUTICALS INC-A (RETA) expected to grow?
The Revenue of REATA PHARMACEUTICALS INC-A (RETA) is expected to grow by 3350.89% in the next year. Check the estimates tab for more information on the RETA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy REATA PHARMACEUTICALS INC-A (RETA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RETA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RETA, evaluating the profitability, health, valuation and growth aspects
- REATA PHARMACEUTICALS INC-A (RETA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REATA PHARMACEUTICALS INC-A (RETA) Sales and EPS estimates to see what analysts future expectations are.
- REATA PHARMACEUTICALS INC-A (RETA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REATA PHARMACEUTICALS INC-A (RETA) Insider and Institutional Ownership to learn about the owners and their transactions.
- REATA PHARMACEUTICALS INC-A (RETA) Stock Chart to make your own analysis
- REATA PHARMACEUTICALS INC-A (RETA) Latest news and press-releases to stay up to date.
Does REATA PHARMACEUTICALS INC-A (RETA) stock pay dividends?
RETA does not pay a dividend.
When does REATA PHARMACEUTICALS INC-A (RETA) report earnings?
REATA PHARMACEUTICALS INC-A (RETA) will report earnings on 2023-11-06, before the market open.
What is the Price/Earnings (PE) ratio of REATA PHARMACEUTICALS INC-A (RETA)?
REATA PHARMACEUTICALS INC-A (RETA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.98).
RETA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RETA. When comparing the yearly performance of all stocks, RETA is one of the better performing stocks in the market, outperforming 99.84% of all stocks.
RETA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RETA. RETA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RETA Financial Highlights
Over the last trailing twelve months RETA reported a non-GAAP Earnings per Share(EPS) of -2.98. The EPS increased by 64.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.43% | ||
| ROE | -100.38% | ||
| Debt/Equity | 0.84 |
RETA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 53% to RETA. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 20.24% and a revenue growth 3350.89% for RETA